➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Moodys
Mallinckrodt
Medtronic
Baxter
Dow
Boehringer Ingelheim

Last Updated: August 10, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR PEMETREXED

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Pemetrexed

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00003711 Combination Chemotherapy in Treating Patients With Metastatic Solid Tumors Completed San Antonio Cancer Institute Phase 1 1997-09-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of combination chemotherapy with pemetrexed disodium and irinotecan in treating patients who have metastatic solid tumors.
NCT00005636 Cisplatin With or Without Pemetrexed Disodium in Treating Patients With Malignant Mesothelioma of the Pleura That Cannot be Removed by Surgery Completed National Cancer Institute (NCI) Phase 3 1999-11-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if cisplatin is more effective with or without pemetrexed disodium for malignant mesothelioma of the pleura. PURPOSE: Randomized phase III trial to compare the effectiveness of cisplatin with or without pemetrexed disodium in treating patients who have malignant mesothelioma of the pleura that cannot be removed by surgery.
NCT00005636 Cisplatin With or Without Pemetrexed Disodium in Treating Patients With Malignant Mesothelioma of the Pleura That Cannot be Removed by Surgery Completed Memorial Sloan Kettering Cancer Center Phase 3 1999-11-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if cisplatin is more effective with or without pemetrexed disodium for malignant mesothelioma of the pleura. PURPOSE: Randomized phase III trial to compare the effectiveness of cisplatin with or without pemetrexed disodium in treating patients who have malignant mesothelioma of the pleura that cannot be removed by surgery.
NCT00006007 LY231514 Plus Gemcitabine in Treating Women With Metastatic Breast Cancer Completed National Cancer Institute (NCI) Phase 2 2000-12-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining LY231514 plus gemcitabine in treating women who have metastatic breast cancer.
NCT00006007 LY231514 Plus Gemcitabine in Treating Women With Metastatic Breast Cancer Completed Alliance for Clinical Trials in Oncology Phase 2 2000-12-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining LY231514 plus gemcitabine in treating women who have metastatic breast cancer.
NCT00022646 Pemetrexed Disodium Plus Gemcitabine in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Completed National Cancer Institute (NCI) Phase 2 2001-08-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving more than one drug and giving the drugs in different ways may kill more tumor cells. PURPOSE: Randomized phase II trial to compare the effectiveness of three different regimens of pemetrexed disodium plus gemcitabine in treating patients who have locally advanced or metastatic non-small cell lung cancer.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Pemetrexed

Condition Name

Condition Name for Pemetrexed
Intervention Trials
Non-small Cell Lung Cancer 109
Lung Cancer 64
Non Small Cell Lung Cancer 54
Carcinoma, Non-Small-Cell Lung 41
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Pemetrexed
Intervention Trials
Carcinoma, Non-Small-Cell Lung 412
Lung Neoplasms 405
Mesothelioma 85
Adenocarcinoma 38
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Pemetrexed

Trials by Country

Trials by Country for Pemetrexed
Location Trials
France 88
Korea, Republic of 82
Japan 74
Belgium 56
Brazil 52
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Pemetrexed
Location Trials
California 112
New York 107
Illinois 98
Pennsylvania 97
Texas 96
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Pemetrexed

Clinical Trial Phase

Clinical Trial Phase for Pemetrexed
Clinical Trial Phase Trials
Phase 4 15
Phase 3 120
Phase 2/Phase 3 8
[disabled in preview] 548
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Pemetrexed
Clinical Trial Phase Trials
Completed 255
Recruiting 144
Not yet recruiting 128
[disabled in preview] 161
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Pemetrexed

Sponsor Name

Sponsor Name for Pemetrexed
Sponsor Trials
Eli Lilly and Company 161
National Cancer Institute (NCI) 92
AstraZeneca 28
[disabled in preview] 69
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Pemetrexed
Sponsor Trials
Other 556
Industry 460
NIH 92
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Dow
Colorcon
Mallinckrodt
Boehringer Ingelheim
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.